2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Imaging, Omics Technologies, Bioinformatics, Computational Biology, Treatment Considerations, Drug Development, Biological Therapies, Transplantation, Immunotherapy, Infusion, Monoclonal Antibody Therapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Microbiome, Clinical Practice (Health Services and Quality), Diseases, Bone Marrow Failure Syndromes, Immunology, GVHD, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, ALL, CLL, Research, Fundamental Science, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric, Animal Model
PAPER

6006 Early vedolizumab combined with first-line therapy for gastrointestinal acute graft-versus-host disease: A single-center real-world study

Jieya Luo, Xinhui Zheng2, Wenhao Wang3, Jingqi Li, N/A4, Xin Chen5, Erlie Jiang, MD6
1 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College., Tianjin, China, Tianjin Institutes of Health Science, Tianjin, China
2 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College., Tianjin, China, Tianjin Institutes of Health Science, Tianjin, China
3 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College., Tianjin, China, Tianjin Institutes of Health Science, Tianjin, China
4 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College., Tianjin, China, Tianjin Institutes of Health Science, Tianjin, China
5 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College., Tianjin, China, Tianjin Institutes of Health Science, Tianjin, China
6 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College., Tianjin, China, Tianjin Institutes of Health Science, Tianjin, China

Background

Systemic corticosteroids remain the standard first-line therapy for gastrointestinal acute graft-versus-host disease (GI-aGVHD), but incomplete intestinal responses and infection risk from prolonged high-dose exposure highlight the need for organ-targeted adjunctive strategies. Vedolizumab (VDZ), a gut-selective anti-α4β7 integrin antibody, inhibits lymphocyte trafficking to the intestine. We evaluated the efficacy, steroid-sparing effect, and safety of early VDZ combined with first-line therapy for GI-aGVHD.

Methods

This study used 1:2 propensity score matching to compare patients who received VDZ within 0–2 days after aGVHD onset as part of first-line therapy (VDZ group, n=33) with those receiving best available therapy without VDZ (non-VDZ group, n=60). The propensity score model included GI-aGVHD severity at treatment initiation, maximum GI-aGVHD grade, baseline corticosteroid dose, and first-line regimen. All response outcomes were assessed from the date of aGVHD onset. The primary endpoint was the day 28 overall response rate (ORR); secondary endpoints included ORR at predefined time points, corticosteroid tapering, infections, and hematologic adverse events.

Results

Baseline characteristics were generally balanced, with approximately 75% of patients reaching grade III–IV aGVHD at maximum severity. Day 28 ORR was comparable between the VDZ and non-VDZ groups (45.5% vs. 35.0%, P=0.322), with no significant differences in day 7 ORR (12.1% vs. 5.0%, P=0.240), day 14 ORR (21.2% vs. 20.0%, P=0.890), day 56 ORR (51.5% vs. 60.0%, P=0.429), or overall ORR (60.6% vs. 71.7%, P=0.275). Median time to complete response was numerically shorter in the VDZ group (27 vs. 33 days, P=0.128).

Subgroup analyses showed no statistically significant difference in day 28 ORR between the VDZ and non-VDZ groups among patients with grade I gastrointestinal involvement at onset (54.2% vs. 34.0%, P=0.103) or among those with grade II–IV gastrointestinal involvement (22.2% vs. 38.5%, P=0.648). Similarly, no significant difference was observed when patients were stratified by overall aGVHD severity, with day 28 ORR of 71.4% versus 61.5% in grade II–III aGVHD (P=0.730) and 26.3% versus 14.7% in grade IV aGVHD (P=0.465). In the corticosteroid-only first-line backbone subgroup, VDZ was associated with a higher ORR that did not reach statistical significance (75.0% vs. 18.2%, P=0.077). Notably, among patients requiring ≥3 non-corticosteroid therapeutic agents, VDZ was associated with a significantly higher day 28 ORR (38.1% vs. 11.5%, P=0.043). Firth-penalized multivariable logistic regression further suggested greater VDZ benefit in patients with initial grade I intestinal involvement (OR=0.06, P=0.041) or isolated gastrointestinal involvement (OR=0.06, P=0.011), whereas concomitant infection at aGVHD treatment was associated with overall treatment failure (OR=14.38, P=0.027).

Although VDZ did not significantly improve ORR, it was associated with faster corticosteroid tapering. Generalized additive mixed model analysis showed a more rapid decline in corticosteroid dose in the VDZ group (P=0.024), mainly during days 0-14 (P=0.025). Consistently, more patients receiving VDZ achieved a ≥50% corticosteroid dose reduction within 14 days (51.5% vs. 28.3%, P=0.026), whereas day 28 tapering success was comparable between groups (60.6% vs. 58.3%, P=0.833). Fecal calprotectin, an intestinal inflammatory marker, declined more rapidly in the VDZ group during days 9-28 (P=0.009). VDZ was not associated with an increased risk of infectious events or grade 3-4 hematologic adverse events. Within 4 months after treatment, the incidences of cytomegalovirus reactivation (9.1% vs. 15.0%, P=0.529), Epstein-Barr virus reactivation (15.2% vs. 28.3%, P=0.152), pulmonary infection (39.4% vs. 46.7%, P=0.449), and severe infection (24.2% vs. 28.3%, P=0.670) were comparable between the VDZ and non-VDZ groups.

 Conclusion

Early VDZ combined with first-line therapy did not significantly improve the day 28 ORR in GI-aGVHD. However, it may facilitate earlier intestinal improvement and faster corticosteroid tapering, particularly in patients with milder initial gastrointestinal involvement or isolated gastrointestinal disease, without increasing infectious or hematologic toxicity.

Jieya Luo: No relevant conflicts of interest to declare.